Article
Genomic hallmarks of localized, non-indolent prostate cancer.
Nature - 19 Jan 2017
Fraser Michael, Sabelnykova Veronica Y, Yamaguchi Takafumi N, Heisler Lawrence E, Livingstone Julie, Huang Vincent, Shiah Yu-Jia, Yousif Fouad, Lin Xihui, Masella Andre P, Fox Natalie S, Xie Michael, Prokopec Stephenie D, Berlin Alejandro, Lalonde Emilie, Ahmed Musaddeque, Trudel Dominique, Luo Xuemei, Beck Timothy A, Meng Alice, Zhang Junyan, D'Costa Alister, Denroche Robert E, Kong Haiying, Espiritu Shadrielle Melijah G, Chua Melvin L K, Wong Ada, Chong Taryne, Sam Michelle, Johns Jeremy, Timms Lee, Buchner Nicholas B, Orain Michèle, Picard Valérie, Hovington Helène, Murison Alexander, Kron Ken, Harding Nicholas J, P'ng Christine, Houlahan Kathleen E, Chu Kenneth C, Lo Bryan, Nguyen Francis, Li Constance H, Sun Ren X, de Borja Richard, Cooper Christopher I, Hopkins Julia F, Govind Shaylan K, Fung Clement, Waggott Daryl, Green Jeffrey, Haider Syed, Chan-Seng-Yue Michelle A, Jung Esther, Wang Zhiyuan, Bergeron Alain, Dal Pra Alan, Lacombe Louis, Collins Colin C, Sahinalp Cenk, Lupien Mathieu, Fleshner Neil E, He Housheng H, Fradet Yves, Tetu Bernard, van der Kwast Theodorus, McPherson John D, Bristow Robert G, Boutros Paul C
Abstract excerpt
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a...
Topics
Join the communities discussing this publication.